Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CTNNB1 S45P |
| Therapy | WNTinib |
| Indication/Tumor Type | hepatocellular carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CTNNB1 S45P | hepatocellular carcinoma | sensitive | WNTinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, WNTinib inhibited Ezh2 phosphorylation and viability in patient-derived hepatocellular carcinoma cell lines harboring CTNNB1 S45P in culture (PMID: 37537299). | 37537299 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37537299) | WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. | Full reference... |